A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

NCT02586051 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Failure, Chronic

Interventions

DRUG: Obinutuzumab
DRUG: Intravenous Immunoglobulin

Sponsor

Hoffmann-La Roche